Incyte INCY
NASDAQ INCY
$127.36 -0.64 (-0.50%)
As of: Sep 4, 2026 · 3:34 PM EDT

Incyte (INCY) Cash from Investing Activities (2010 - 2026)

Incyte's (INCY) quarterly Cash from Investing Activities came in at -$51.8 million in Q2 2026, down 174.44% YoY from $69.6 million in Q2 2025, and up 41.28% on a QoQ basis from -$88.2 million in Q1 2026.

Analysis

Incyte (INCY) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Incyte (INCY) has 17 years of Cash from Investing Activities data on file, last reported at -$51.8 million in Q2 2026.

  • Quarterly Cash from Investing Activities fell 174.44% year-over-year to -$51.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$224.8 million (down 23174.43% YoY) and the FY2025 annual result came in at -$102.6 million, down 165.14% from the prior year.
  • Cash from Investing Activities climbed to -$51.8 million in Q2 2026, from -$88.2 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $213.8 million in Q2 2024 to a low of -$154.5 million in Q4 2023.
  • A 5-year average of -$20.6 million and a median of -$21.2 million in 2022 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2024 — Cash from Investing Activities surged 2978.18% — and 2026, when it tumbled 8140.38%.
  • Tracing INCY's Cash from Investing Activities over 5 years: stood at -$20.9 million in 2022, then tumbled by 638.81% to -$154.5 million in 2023, then surged by 86.11% to -$21.5 million in 2024, then tumbled by 74.33% to -$37.4 million in 2025, then sank by 38.41% to -$51.8 million in 2026.
  • The last three Cash from Investing Activities figures came in at -$51.8 million (Q2 2026), -$88.2 million (Q1 2026), and -$37.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.31 Bn 130.45 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.17 Bn 77.17 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.25 Bn 58.07 Bn 1.37 Bn -
4 Moderna 58.27 Bn 53.13 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.02 Bn 44.02 Bn - -1.66 Bn
6 BeOne Medicines 40.01 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.26 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - -229.72 Mn
9 Insmed 27.37 Bn 26.21 Bn 358.27 Mn 24.51 Mn
10 Incyte 25.53 Bn 21.00 Bn 1.57 Bn -51.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -51.79 Mn
Mar 31, 2026 -88.20 Mn
Dec 31, 2025 -37.42 Mn
Sep 30, 2025 -47.42 Mn
Jun 30, 2025 -18.87 Mn
Mar 31, 2025 1.10 Mn
Dec 31, 2024 -21.47 Mn
Sep 30, 2024 38.27 Mn
Jun 30, 2024 213.82 Mn
Mar 31, 2024 -73.11 Mn
Dec 31, 2023 -154.50 Mn
Sep 30, 2023 -17.19 Mn
Jun 30, 2023 -7.43 Mn
Mar 31, 2023 -28.56 Mn
Dec 31, 2022 -20.91 Mn
Sep 30, 2022 -28.40 Mn
Jun 30, 2022 -12.48 Mn
Mar 31, 2022 -16.75 Mn
Dec 31, 2021 -66.05 Mn
Sep 30, 2021 -32.75 Mn